Full Text
EE251 Cost-Effectiveness of First-Line Lorlatinib for ALK-Positive Advanced NSCLC in the UK

Abstract

Authors

Daniel Ladino Victoria Brodbin Carina Marie Behr Ian Gould Hannah Le

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×